| Literature DB >> 26371757 |
James T Rosenbaum1, Dongseok Choi2, Amanda Wong3, David J Wilson3, Hans E Grossniklaus4, Christina A Harrington5, Roger A Dailey3, John D Ng3, Eric A Steele3, Craig N Czyz6, Jill A Foster7, David Tse8, Chris Alabiad8, Sander Dubovy8, Prashant K Parekh8, Gerald J Harris9, Michael Kazim10, Payal J Patel10, Valerie A White11, Peter J Dolman11, Deepak P Edward12, Hind M Alkatan12, Hailah Al Hussain12, Dinesh Selva13, R Patrick Yeatts14, Bobby S Korn15, Don O Kikkawa15, Patrick Stauffer3, Stephen R Planck1.
Abstract
BACKGROUND: Although thyroid eye disease is a common complication of Graves' disease, the pathogenesis of the orbital disease is poorly understood. Most authorities implicate the immune response as an important causal factor. We sought to clarify pathogenesis by using gene expression microarray.Entities:
Mesh:
Year: 2015 PMID: 26371757 PMCID: PMC4570801 DOI: 10.1371/journal.pone.0137654
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Ages for each experimental group.
| Set 1 | Set 2 | |||
|---|---|---|---|---|
| Diagnosis | N | Mean age at biopsy | N | Mean age at biopsy |
| NSOI | 14 | 44.0 ± 21.8 | 11 | 58.5 ± 24.1 |
| Sarcoid | 1 | 60.6 | 7 | 48.8 ± 14.7 |
| TED | 14 | 54.0 ± 14.7 | 11 | 48.6 ± 13.0 |
| GPA | 4 | 43.4 ± 14.3 | 4 | 40.0 ± 13.9 |
| Normal | 14 | 61.0 ± 15.6 | 6 | 69.7 ± 9.8 |
*one repeated from set 1;
**two repeated from set 1
Fig 1Principal component analysis based on significantly up-regulated and significantly down-regulated probe sets in TED orbital adipose (T) against uninflamed controls (C).
The discovery set (Set 1) had 36 significantly up-regulated and 254 significantly down-regulated probe sets. The validation set (Set 2) had 66 significantly up-regulated and 604 significantly down-regulated probe sets. At least 1.5-fold change with FDR adjusted p-value < 0.05 is considered statistically significant.
Probe sets with a significantly lower signal in orbital tissue from TED subjects compared to uninflamed controls.
| Set 1 | Set 2 | |||||
|---|---|---|---|---|---|---|
| Probe Set | Gene Symbol | Gene Title | Fold Difference | FDR p-value | Fold Difference | FDR p-value |
| 203305_at | F13A1 | coagulation factor XIII, A1 polypeptide | -3.87 | 0.012 | -3.10 | 0.019 |
| 213800_at | CFH | complement factor H | -3.52 | 0.022 | -3.05 | 0.002 |
| 207277_at | CD209 | CD209 molecule | -4.25 | 0.006 | -2.24 | 0.027 |
| 203407_at | PPL | periplakin | -2.69 | 0.025 | -3.46 | 0.009 |
| 209348_s_at | MAF | v-maf musculoaponeurotic fibrosarcoma oncogene homolog (avian) | -3.56 | 0.046 | -2.54 | 0.040 |
| 201212_at | LGMN | legumain | -3.62 | 0.007 | -2.38 | 0.005 |
| 215039_at | LOC339524 | uncharacterized LOC339524 | -3.75 | 0.011 | -2.16 | 0.024 |
| 237351_at | LOC100652994 | uncharacterized LOC100652994 | -3.73 | 0.000 | -2.03 | 0.028 |
| 215870_s_at | PLA2G5 | phospholipase A2, group V | -3.30 | 0.002 | -2.15 | 0.019 |
| 1554485_s_at | TMEM37 | transmembrane protein 37 | -3.46 | 0.001 | -1.88 | 0.023 |
| 240873_x_at | DAB2 | Dab, mitogen-responsive phosphoprotein, homolog 2 (Drosophila) | -2.79 | 0.029 | -2.40 | 0.005 |
| 1555729_a_at | CD209 | CD209 molecule | -2.51 | 0.009 | -2.27 | 0.028 |
| 203414_at | MMD | monocyte to macrophage differentiation-associated | -2.64 | 0.036 | -2.07 | 0.045 |
| 213001_at | ANGPTL2 | angiopoietin-like 2 | -2.60 | 0.013 | -2.02 | 0.041 |
| 232712_at | --- | --- | -2.70 | 0.044 | -1.82 | 0.031 |
| 209543_s_at | CD34 | CD34 molecule | -2.31 | 0.043 | -2.11 | 0.049 |
| 228347_at | SIX1 | SIX homeobox 1 | -2.37 | 0.036 | -2.00 | 0.034 |
| 206856_at | LILRB5 | leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 5 | -2.74 | 0.008 | -1.61 | 0.030 |
| 231846_at | FOXRED2 | FAD-dependent oxidoreductase domain containing 2 | -2.23 | 0.039 | -2.10 | 0.012 |
| 226841_at | MPEG1 | macrophage expressed 1 | -2.26 | 0.031 | -2.05 | 0.020 |
| 206178_at | PLA2G5 | phospholipase A2, group V | -2.27 | 0.003 | -1.82 | 0.024 |
| 206726_at | HPGDS | hematopoietic prostaglandin D synthase | -2.17 | 0.006 | -1.89 | 0.008 |
| 244111_at | KRT222 | keratin 222 | -2.39 | 0.023 | -1.65 | 0.043 |
| 238151_at | --- | --- | -2.21 | 0.003 | -1.74 | 0.029 |
| 204829_s_at | FOLR2 | folate receptor 2 (fetal) | -2.25 | 0.003 | -1.57 | 0.040 |
| 222876_s_at | ADAP2 | ArfGAP with dual PH domains 2 | -2.10 | 0.012 | -1.69 | 0.035 |
| 225228_at | DRAM2 | DNA-damage regulated autophagy modulator 2 | -1.88 | 0.048 | -1.60 | 0.031 |
| 218032_at | SNN | stannin | -1.68 | 0.020 | -1.51 | 0.024 |
| 218633_x_at | ABHD10 | abhydrolase domain containing 10 | -1.53 | 0.031 | -1.50 | 0.048 |
Fig 2Principal component analysis reveals that gene expression in TED orbital adipose is more similar to uninflamed controls than to tissues from subjects with sarcoidosis, GPA, or NSOI.
C = control. T = TED. N = NSOI. S = Sarcoidosis. G = GPA. Set 1 is based on the discovery set and Set2 is based on the validation set.
Fig 3A dendrogram produced by hierarchical cluster analysis and an independently created heat map of signals for immunoglobulin, cytokine, and cytokine receptor transcripts compares the expression profiles of subjects within each disease group in array dataset 2.
The heat maps were created with the GSEA program comparing probe set signal levels for subjects in branches A and B versus branches C and D. Genes with the highest signals in branches A and B are at the top of each section. The end branch labels are N—NSOI, S—sarcoidosis, G—GPA, T—TED, C—control.
Fig 4Heat map showing relative chemokine and chemokine receptor expression aligned with the same dendrogram shown in Fig 3.